Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980700 | 0.89 | KDM4E (0.56) | HSP90AB1HCRTR1HCRTR2KDM4EPTPN11 | |
| SCHEMBL4978905 | 0.87 | LMNA (0.47) | HSP90AB1HCRTR1HCRTR2KDM4EMAPT | |
| SCHEMBL4976769 | 0.87 | TSHR (0.48) | HSP90AB1HCRTR1HCRTR2KDM4EPTPN11 | |
| SCHEMBL4978889 | 0.87 | GBA1 (0.47) | HSP90AB1HCRTR1HCRTR2PTPN11HSP90AA1 | |
| SCHEMBL4976947 | 0.87 | MEN1 (0.53) | HSP90AB1HCRTR1HCRTR2KDM4EPTPN11 | |
| SCHEMBL4980609 | 0.86 | HSP90AB1 (0.40) | HSP90AB1KDM4EPTPN11MAPTHRH3 | |
| SCHEMBL4978109 | 0.86 | HSP90AB1 (0.46) | HSP90AB1HCRTR1HCRTR2KDM4EPTPN11 | |
| SCHEMBL4976400 | 0.85 | HSP90AB1 (0.47) | HSP90AB1HCRTR1HCRTR2KDM4EPTPN11 | |
| SCHEMBL4973602 | 0.84 | HSP90AB1 (0.49) | HSP90AB1HSD11B1MGLLHRH3 | |
| SCHEMBL4976903 | 0.84 | HRH3 (0.47) | HSP90AB1HCRTR1HCRTR2MGLLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HSP90AB1 2652/4885HSD11B1 4086/4885HCRTR1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.